Intranasal COVID vaccine INCOVACC will be global game changer, says Bharat Biotech Chairman

Published On 2022-09-08 10:26 GMT   |   Update On 2022-09-08 10:26 GMT

Bharat Biotech's iNCOVACC, the world's first intranasal vaccine for Covid-19 which received approval for emergency use in India on Tuesday, will be a global game changer in intranasal vaccines technology and delivery systems, the vaccine maker's Chairman and Managing Director Dr. Krishna Ella said.Bharat Biotech International Ltd (BBIL), a global leader in vaccine innovation and developer...

Login or Register to read the full article

Bharat Biotech's iNCOVACC, the world's first intranasal vaccine for Covid-19 which received approval for emergency use in India on Tuesday, will be a global game changer in intranasal vaccines technology and delivery systems, the vaccine maker's Chairman and Managing Director Dr. Krishna Ella said.

Bharat Biotech International Ltd (BBIL), a global leader in vaccine innovation and developer of vaccines for infectious diseases, announced that iNCOVACC (BBV154), has received approval under restricted use in emergency situations for ages 18 and above.

Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News